Buchumschlag

Development of a highly effective combination monoclonal antibody therapy against Herpes simplex virus

Infections with Herpes simplex virus (HSV)-1 or -2 usually present as mild chronic recurrent disease, however in rare cases can result in life-threatening conditions with a large spectrum of pathology. Monoclonal antibody therapy has great potential especially to treat infections with virus resistan...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Seyfizadeh, Narges (VerfasserIn) , Kalbermatter, David (VerfasserIn) , Imhof, Thomas (VerfasserIn) , Ries, Moritz (VerfasserIn) , Müller, Christian (VerfasserIn) , Jenner, Leonie (VerfasserIn) , Blumenschein, Elisabeth (VerfasserIn) , Yendrzheyevskiy, Alexandra (VerfasserIn) , Grün, Frank (VerfasserIn) , Moog, Kevin (VerfasserIn) , Eckert, Daniel (VerfasserIn) , Engel, Ronja (VerfasserIn) , Diebolder, Philipp (VerfasserIn) , Chami, Mohamed (VerfasserIn) , Krauß, Jürgen (VerfasserIn) , Schaller, Torsten (VerfasserIn) , Arndt, Michaela (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2024
In: Journal of biomedical science
Year: 2024, Jahrgang: 31, Pages: 1-22$p22
ISSN:1423-0127
DOI:10.1186/s12929-024-01045-2
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12929-024-01045-2
Verlag, lizenzpflichtig, Volltext: https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-024-01045-2
Volltext
Verfasserangaben:Narges Seyfizadeh, David Kalbermatter, Thomas Imhof, Moritz Ries, Christian Müller, Leonie Jenner, Elisabeth Blumenschein, Alexandra Yendrzheyevskiy, Frank Grün, Kevin Moog, Daniel Eckert, Ronja Engel, Philipp Diebolder, Mohamed Chami, Jürgen Krauss, Torsten Schaller and Michaela Arndt
Beschreibung
Zusammenfassung:Infections with Herpes simplex virus (HSV)-1 or -2 usually present as mild chronic recurrent disease, however in rare cases can result in life-threatening conditions with a large spectrum of pathology. Monoclonal antibody therapy has great potential especially to treat infections with virus resistant to standard therapies. HDIT101, a humanized IgG targeting HSV-1/2 gB was previously investigated in phase 2 clinical trials. The aim of this study was to develop a next-generation therapy by combining different antiviral monoclonal antibodies.
Beschreibung:Veröffentlicht: 28 May 2024
Gesehen am 11.06.2025
Beschreibung:Online Resource
ISSN:1423-0127
DOI:10.1186/s12929-024-01045-2

Ähnliche Einträge